RHHVF - Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space Analyst Sees Short-Term Challenges | Benzinga
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY) for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD).
Roche gains exclusive worldwide rights and will be responsible for clinical development, manufacturing, and commercialization.
Under the terms of the agreement, Ionis will be responsible for advancing the two programs through pre-clinical studies; Roche will have sole responsibility for clinical development and, if approved, commercialization worldwide.
Ionis will receive a ...